

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ahlsson Anders	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Sanofi Aventis : Atrial fibrillation symposium speakers fee year 2008: 500 Euro (2014-2015-2016)</p> <p>D - Research funding (departmental or institutional).            - Örebro university hospital Research committee : Financial support for studies years 2008-2013 (2014-2015-2016)            - Vingmed / Estech : Microwave ablation study year 2008: 5000 Euro (2014-2015-2016)            - Swedish Society of Medicine : Financial support for studies (2016)</p>
Atar Dan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Novartis : Acute Heart Failure (2014-2015-2016)            - Cardiome : antiarrhythmic drugs (2014-2015-2016)            - Boehringer-Ingelheim : Anticoagulants (2014-2015-2016)            - BMS/Pfizer : anticoagulants (2014-2015-2016)            - Bayer Healthcare : anticoagulants (2014-2015-2016)            - Merck Sharp &amp; Dohme : Antithrombotic therapy (2014-2015-2016)            - Vifor International : Heart failure (2014-2015-2016)            - Astra Zeneca : Platelet inhibition (2014-2015-2016)            - KYMA Medical : Remote monitoring in heart failure (2014-2015-2016)            - St Jude Medical : Devices (2016)            - Roche Pharma : Myocardial protection drugs (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - TIMI group : atherosclerosis-modifying agents (2014-2015-2016)            - Duke Research Unit : Heart Failure Therapy (2014-2015-2016)            - Pfizer : Post infarction therapy for myocardial protection (2014-2015-2016)</p> <p>D - Research funding (departmental or institutional).            - EU-FP-7 grant / Trophos, Marseille : Prevention of Reperfusion Injury in STEMI (Leader of Clinical Research Consortium) (2014)</p>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Benussi Stefano	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AB Medica : AF Ablation (2014)</li> <li>- Maquet Inc. : Left atrial appendage management (2014)</li> <li>- Atricure Inc. : AF Ablation (2014-2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic Inc. : AF Ablation (2014)</li> <li>- Estech Inc. : AF Ablation (2014)</li> </ul>
Casadei Barbara	Nothing to be declared (2014-2015-2016)
Castella Pericas Manuel	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Atricure : talk in courses, course organization (2014)</li> <li>- Medtronic : talks in courses (2014)</li> <li>- Atricure : Atrial fibrillation (2015-2016)</li> <li>- Medtronic : Valves, atrial fibrillation (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sorin Group : heart valves (2014)</li> <li>- Medtronic : Heart valves, catheters, AF (2014)</li> <li>- Edwards Lifesciences : heart valves, surgery, canulae (2014)</li> <li>- Medtronic : atrial fibrillation (2015-2016)</li> <li>- Edwards Lifesciences : valves, atrial fibrillation (2015-2016)</li> </ul>
Diener Hans-Christoph	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Allergan : Spasticity (2014-2015)</li> <li>- Abbott : Stroke (2014-2015)</li> <li>- Novartis : Stroke (2014-2015)</li> <li>- GlaxoSmithKline : Stroke (2014-2015)</li> <li>- Ev3 : Stroke (2014-2015)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Diener Hans-Christoph	<ul style="list-style-type: none"> <li>- D-Pharm : Stroke (2014-2015)</li> <li>- Paion : Stroke (2014-2015)</li> <li>- Astra Zeneca : Stroke (2014-2015-2016)</li> <li>- Boehringer-Ingelheim : Stroke (2014-2015-2016)</li> <li>- Covidien : Stroke (2014-2015-2016)</li> <li>- Daiichi Sankyo : Stroke (2014-2015-2016)</li> <li>- Medtronic : Stroke (2014-2015-2016)</li> <li>- Pfizer : Stroke (2014-2015-2016)</li> <li>- Servier : Stroke (2014-2015-2016)</li> <li>- Sanofi Aventis : Stroke (2014-2015-2016)</li> <li>- Bayer Healthcare : Stroke (2014-2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Stroke (2014-2015-2016)</li> <li>- CoAxia : Stroke (2014-2015-2016)</li> <li>- Neurobiological technologies : Stroke (2014-2015-2016)</li> <li>- Thrombogenics : Stroke (2014-2015-2016)</li> <li>- Bristol Myers Squibb : Stroke Prevention (2014-2015-2016)</li> <li>- St. Jude : Stroke, LAA occlusion (2014-2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- NIH : Stroke (2014-2015)</li> <li>- German Stroke Foundation : Stroke (2014-2015-2016)</li> <li>- German Research Foundation : Stroke (2014-2015-2016)</li> <li>- German Ministry of Education and Research (BMBF) : Stroke (2014-2015-2016)</li> <li>- Hein-Nixdorf Foundation : Stroke (2014-2015-2016)</li> </ul> </li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Heidbuchel Hein	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : anti-arrhythmic (2014)</li> <li>- Medtronic : devices (2014)</li> <li>- Cardiome AG : anti-arrhythmic (2014-2015-2016)</li> <li>- Pfizer : anticoagulation (2014-2015-2016)</li> <li>- Bristol Myers Squibb : anticoagulation (2014-2015-2016)</li> <li>- Bayer : anticoagulation, anti-anginal (2014-2015-2016)</li> <li>- Boehringer-Ingelheim : anticoagulation, hypertension (2014-2015-2016)</li> <li>- Biotronik : devices (2014-2015-2016)</li> <li>- Daiichi Sankyo : statins, oral anticoagulants (2014-2015-2016)</li> <li>- Flemisch Organisation Sports Medicine : congress organiser (2015-2016)</li> <li>- Downtown Europe : congress organiser (Belg Soc Cardiol meeting) (2015-2016)</li> <li>- Correvio International : education (2015-2016)</li> <li>- WebMD : Educational video recording (2015-2016)</li> <li>- PeerVoice : Educational video recordings (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulation (2016)</li> <li>- Pfizer/BMS : anticoagulation (2016)</li> </ul>
Hendriks Jeroen	<p>Nothing to be declared (2015-2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Honorarium for presentation (2014)</li> <li>- Sanofi Aventis : Honorarium for presentation (2014)</li> <li>- Bristol Myers Squibb : Honorarium for presentation (2014)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hindricks Gerhard	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biotronik : ICD, CRT (2014)</li> <li>- Boston Scientific : IC, CRT, Catheter Ablation (2014-2015)</li> <li>- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- Biotronik : ICD CRT (2015)</li> <li>- Boston Scientific : CIEDs and interventional electrophysiology (2016)</li> <li>- Biotronik : CIEDs and interventional electrophysiology (2016)</li> <li>- Boehringer-Ingelheim : Pharma (2016)</li> <li>- Zoll Medical : wearable defibrillator (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, anticoagulation (2014-2015)</li> <li>- Boston Scientific : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- St Jude Medical : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- Biotronik : ICD, CRT, Catheter Ablation (2014-2015)</li> <li>- Zoll Medical : wearable ICD (2014-2015)</li> <li>- Boston Scientific : CIEDs and interventional electrophysiology (2016)</li> <li>- St Jude Medical : CIEDs and interventional electrophysiology (2016)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : cardiovascular (2014)</li> <li>- Pfizer : cardiovascular (2014)</li> <li>- Bristol Myers Squibb : cardiovascular (2014)</li> <li>- Medtronic : cardiovascular (2014-2015)</li> <li>- St Jude Medical : cardiovascular (2014-2015)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2014-2015)</li> <li>- Medscape : cardiovascular (2014-2015)</li> <li>- Boehringer-Ingelheim : cardiovascular (2014-2015-2016)</li> <li>- Astra Zeneca : cardiovascular (2015)</li> <li>- Servier : cardiovascular (2015)</li> <li>- Bayer Vital : cardiovascular (2015)</li> <li>- Correvio : cardiovascular (2015)</li> <li>- Bristol Myers Squibb Global : cardiovascular (2015)</li> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015-2016)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015-2016)</li> <li>- Pfizer Global : cardiovascular (2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : cardiovascular (2014-2015-2016)</li> <li>- St Jude Medical : cardiovascular (2014-2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015-2016)</li> <li>- British Heart Foundation : cardiovascular (2014-2015-2016)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015-2016)</li> <li>- Leducq Foundation : cardiovascular (2014-2015-2016)</li> <li>- European Union FP7 : cardiovascular (2014-2015-2016)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015-2016)</li> </ul> </li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015-2016)</li> <li>- UK Medical Research Council : cardiovascular (2015-2016)</li> </ul>
Kotecha Dipak	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Beta-blockers/Heart Failure (2014)</li> <li>- Daiichi Sankyo : Atrial fibrillation (2014-2015)</li> <li>- Physicians' Academy for Cardiovascular Education : Atrial fibrillation/Heart Failure (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Menarini : Beta-blockers/Heart Failure (2014-2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- National Institute for Health Research : Career Development Fellowship (2015-2016)</li> </ul>
Manolis Antonis S	Nothing to be declared (2014-2015-2016)
Oldgren Jonas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulants (2014)</li> <li>- Astra Zeneca : Antiplatelets (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Investigator (2014)</li> <li>- Pfizer : Investigator (2014)</li> <li>- Pfizer : Emanate (2015)</li> <li>- Boehringer-Ingelheim : RE-DUAL pci (2015)</li> <li>- Pfizer : Apixaban - Study Executive steering committee member and Advisory board fee (2016)</li> <li>- Boehringer-Ingelheim : Dabigatran - Study Executive steering committee member and speaker fee (2016)</li> </ul>
Popescu Bogdan Alexandru	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GE Healthcare : Imaging (2014-2015-2016)</li> </ul>
Schotten Ulrich	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : Biomarkers for AF (2014)</li> <li>- Bayer AG : experimental positive inotropic agent (2014)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Schotten Ulrich	<ul style="list-style-type: none"> <li>- Roche Diagnostics : Biomarker (2015-2016)</li> <li>- Sorin Group : Mechanisms of AF (2015-2016)</li> <li>- Correvio : Mechanisms of AF (2015-2016)</li> <li>- Bayer Healthcare : Mechanisms of AF (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Roche Diagnostics : Biomarkers for AF (2014)</li> <li>- Medtronic : renal denervation (2014)</li> <li>- Roche Diagnostics : Mechanisms of AF (2015-2016)</li> </ul>
Van Putte Bart	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Atricure : Atrial fibrillation (2014)</li> <li>- Atricure : Afib, minimally invasive and full maze therapies (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Atricure : Minimally invasive thoroscopic Afib ablation (2015-2016)</li> </ul>
Vardas Panagiotis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Speaker fees (2014)</li> <li>- Menarini : Speaker fees (2014)</li> <li>- Bayer : Speaker fees (2014-2015)</li> <li>- Boehringer-Ingelheim : Speaker fees (2014-2015)</li> <li>- MENARINI LUXEMBOURG : CONSULTANCY ACTIVITIES (2015)</li> <li>- Menarini KOREA : CONSULTANCY SERVICES (2015)</li> <li>- Servier : SCIENTIFIC ANALYSIS (2015)</li> <li>- ADIR : Scientific Coordinator (2015)</li> <li>- Pfizer : SPEAKER FEES (2015)</li> <li>- Servier : SPEAKER FEES (2015)</li> </ul>



## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vardas Panagiotis	<ul style="list-style-type: none"> <li>- ELPEN : SPEAKER FEES (2015)</li> <li>- Menarini ASIA : SPEAKER FEES (2015-2016)</li> <li>- Servier : CONSULTANCY FEES (2016)</li> <li>- MENARINI INTERNATIONAL : CONSULTANCY FEES (2016)</li> <li>- PAREXEL INTERNATIONAL : SPEAKER FEES (2016)</li> <li>- BAYER MIDDLE EAST : SPEAKER FEES (2016)</li> <li>- AFEA S.A. : SPEAKER FEES (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : National Coordinator fee (2014)</li> <li>- Boehringer-Ingelheim : Speaker fees, National Coordinator fees (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : 3 different studies (2014)</li> <li>- Novartis : CANTOS Study (2014)</li> <li>- ELPEN : EKVASIS study (2014)</li> <li>- Medtronic : MORE CARE study (2014)</li> <li>- Amgen : OMECAMTIV MECARBIL study (2014)</li> <li>- Servier : SIGNIFY study (2014)</li> <li>- Bayer : X-VERT study (2014)</li> <li>- Boehringer-Ingelheim : RESEARCH STUDY (2015-2016)</li> <li>- Medtronic : RESEARCH STUDY (2015-2016)</li> <li>- Novartis : RESEARCH STUDY (2015-2016)</li> <li>- Sanofi Aventis : RESEARCH STUDY (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Task Force Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vardas Panagiotis	- ELPEN : RESEARCH STUDY (2016) - HELLENIC CARDIOVASCULAR RESEARCH SOCIETY : RESEARCH STUDY (2016)

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Abdelali Salima	Nothing to be declared (2015-2016)
Adragao Pedro Pulido	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosense Webster : Catheter Ablation (2015-2016)
Agewall Stefan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Thermo Fischer Scientific : Cardiac markers (2015) - Vifor International : Heart failure (2015) - Astra Zeneca : Platelet inhibition (2015) - Astra Zeneca : Antiplatelet treatment (2016)
Aliyev Farid	Nothing to be declared (2015-2016)
Anfinsen Ole Gunnar	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Lecture fee (2015) - Bayer : Lecture fee (2015-2016) - Medtronic : Co-chairman at Nordic meeting (2016)
Antoniades Loizos	Nothing to be declared (2015-2016)
Arenal Maiz Angel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosense Webster : Ablation (2015) - Medtronic : ICD and Ablation (2015) - St Jude Medical : ICD and Ablation (2015) - Medtronic : Electrophysiology (2016) - Sorin Group : Electrophysiology (2016) - Biotronik : Electrophysiology (2016) - St. Jude : Electrophysiology (2016)  D - Research funding (departmental or institutional). - Biosense Webster : Ablation (2015) - Biosense Webster : Electrophysiology (2016)

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Baensch Dietmar	Declaration not submitted (2015-2016)
Bajraktari Gani	Nothing to be declared (2015-2016)
Baron Esquivias Gonzalo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Anticoagulation (2015-2016)</li> <li>- Daiichi Sankyo : Anticoagulation (2015-2016)</li> <li>- Pfizer : Anticoagulation (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : Dyslipemia (2015-2016)</li> <li>- Bayer : Anticoagulation (2016)</li> </ul>
Beinart Roy	<p>Nothing to be declared (2016)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Affix Medical : Ablation (2015)</li> <li>- Bayer : NOAC (2015)</li> <li>- Boehringer-Ingelheim : NOAC (2015)</li> <li>- Pfizer : NOAC (2015)</li> </ul>
Braunschweig Frieder	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Ablation catheters (2015-2016)</li> <li>- Boston Scientific : Pacemaker/ICD (2015-2016)</li> <li>- Medtronic : Pacemaker/ICD (2015-2016)</li> <li>- St Jude Medical : Pacemaker/ICD (2015-2016)</li> <li>- Biotronik : Pacemaker/ICD (2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Medtronic : Ablation therapy (2015-2016)</li> </ul>
Budts Werner	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Occlutech : PFO and ASD closure (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Lipids (2015)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Budts Werner	<ul style="list-style-type: none"> <li>- Servier : Atherosclerosis (2015-2016)</li> <li>- Medtronic : Ceraflex - Venus valve (2015-2016)</li> <li>- St Jude Medical : Interventional cardiology (2015-2016)</li> <li>- Occlutech : Interventional cardiology (2015-2016)</li> <li>- Boston Scientific : LAA closure (2015-2016)</li> <li>- Pfizer : Lipids (2015-2016)</li> <li>- Actelion : Pulmonary hypertension (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Occlutech : ASD and PFO closure (2016)</li> <li>- St Jude Medical : LAA closure (2016)</li> </ul>
Camm John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- ChanRx/Laguna : Vanoxerine antiarrhythmic drug (2015)</li> <li>- Johnson &amp; Johnson : Apixaban (2015-2016)</li> <li>- Bristol Myers Squibb : Apixaban (2015-2016)</li> <li>- Sorin Group : Atrial fibrillation (2015-2016)</li> <li>- Eli Lilly : Cardiovascular safety of oncology product (2015-2016)</li> <li>- Wiley Blackwell : Clinical Cardiology (2015-2016)</li> <li>- NeRRe Pharma : CV safety of neurology product (2015-2016)</li> <li>- Boehringer-Ingelheim : Dabigatran and Idarucizumab (2015-2016)</li> <li>- Biotronik : DSMB - Ablation (2015-2016)</li> <li>- Infobionics : ECG monitoring (2015-2016)</li> <li>- Oxford University Press : Europace and ESC textbook (2015-2016)</li> <li>- Boston Scientific : General advice (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Camm John	<ul style="list-style-type: none"> <li>- GlaxoSmithKline : General Advice (2015-2016)</li> <li>- InCarda : Inhaled flecainide (2015-2016)</li> <li>- Servier : Multiple products (2015-2016)</li> <li>- Sanofi Aventis : Multiple products (2015-2016)</li> <li>- Milestone : New calcium channel blocker (2015-2016)</li> <li>- Menarini : Ranolazine (2015-2016)</li> <li>- Gilead : Ranolazine (2015-2016)</li> <li>- Bayer : Rivaroxaban (2015-2016)</li> <li>- Medtronic : Subcutaneous monitoring (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Antiarrhythmic drug (2015)</li> <li>- Thrombosis Research Institute : Anticoagulation for atrial fibrillation (2015-2016)</li> <li>- BMS/Pfizer : Apixaban (2015-2016)</li> <li>- Boehringer Ingelheim : Atrial fibrillation registry (2015-2016)</li> <li>- Daiichi Sankyo : Edoxaban (2015-2016)</li> <li>- Richmond Pharmacology : Many phase 1 NCEs (2015-2016)</li> </ul>
Carerj Scipione	Nothing to be declared (2015-2016)
Casselmann Filip	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Atrial fibrillation (2015-2016)</li> <li>- Edwards Lifesciences : Minimally invasive cardiac surgery (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Atrial fibrillation (2015)</li> <li>- Edwards Lifesciences : Minimally invasive cardiac surgery (2015)</li> </ul>
Chasnoits Alexandr	Nothing to be declared (2015-2016)

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Coca Antonio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Recordati International : Azilsartan; Lercanidipine; combos (2015)</li> <li>- Menarini : Nevibolol; Olmesartan; Olmesartan-Amlodipine; Olmesartan-HCTZ (2015-2016)</li> <li>- Servier : Perindopril; indapamide; combos; triple combinations (2015-2016)</li> <li>- Ferrer Internacional : Torasemide; CardioIncode microchips; Polypill (2015-2016)</li> <li>- Sanofi Aventis : Combination Irbesartan/amlodipine; Alirocumab (2016)</li> </ul>
Csanadi Zoltan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : DOAC (2015)</li> <li>- Medtronic : EP, ablation (2015)</li> <li>- St Jude Medical : EP, ablation (2015)</li> <li>- Biotronik : PM, ICD, catheter ablation (2015)</li> <li>- Boehringer-Ingelheim : DOAC (2015-2016)</li> <li>- Pfizer : DOAC (2015-2016)</li> <li>- Medtronic : ablation (2016)</li> <li>- Biotronik : device therapy (2016)</li> <li>- Bayer AG : DOAC (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : EP, ablation (2015)</li> <li>- Medtronic : ablation, rhythm monitoring (2016)</li> </ul>
Dan Gheorghe-Andrei	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : cardiology (2015)</li> <li>- Abbott : cardiology (2015-2016)</li> <li>- Astra Zeneca : Cardiology (2015-2016)</li> <li>- Boehringer-Ingelheim : cardiology (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Dan Gheorghe-Andrei	<ul style="list-style-type: none"> <li>- Novartis : cardiology (2015-2016)</li> <li>- Pfizer : Cardiology (2015-2016)</li> <li>- Servier : cardiology (2015-2016)</li> <li>- Alfa-Wassermann : cardiology (2015-2016)</li> <li>- Berlin Chemie AG : cardiology (2015-2016)</li> <li>- Bayer AG : cardiology (2015-2016)</li> <li>- Roche Diagnostics : cardiology (2015-2016)</li> <li>- Krka Pharma : cardiology (2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Servier : cardiology (2015-2016)</li> </ul>
De Caterina Raffaele	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Duke Clinical Research Institute : apixaban - APPRAISE-2 National Coordinator (2015)</li> <li>- Roche : dalcetrapib (2015)</li> <li>- Novartis : aliskiren (2015-2016)</li> <li>- BMS/Pfizer : apixaban (2015-2016)</li> <li>- Boehringer-Ingelheim : dabigatran (2015-2016)</li> <li>- Lilly : Diabetes (2015-2016)</li> <li>- Elsevier : Editor-in-Chief, Vascular Pharmacology (2015-2016)</li> <li>- Daiichi Sankyo : edoxaban (2015-2016)</li> <li>- Bayer Schering Pharma : rivaroxaban (2015-2016)</li> <li>- Medscape : anticoagulants (2016)</li> <li>- Merck Sharp &amp; Dohme : vorapaxar (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Aliskiren trials (2015)</li> </ul>



## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
De Caterina Raffaele	<ul style="list-style-type: none"> <li>- Roche : dalcetrapib trials (2015)</li> <li>- Daiichi Sankyo : edoxaban - ENGAGE-AF trial (2015)</li> <li>- Boehringer-Ingelheim : RELY-ABLE trial (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Novartis : aliskiren and canakinumab trials (2016)</li> <li>- Bristol Myers Squibb/Pfizer Alliance : apixaban (2016)</li> <li>- Bayer Schering Pharma : rivaroxaban (2016)</li> </ul> </li> </ul>
Deftereos Spyridon	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- ELPEN Pharmaceutical Company : Antiarrhythmic pharmacotherapy (2015-2016)</li> <li>- Medtronic : Cardiac Electrophysiology (2015-2016)</li> <li>- Johnson &amp; Johnson : Cardiac Electrophysiology (2015-2016)</li> <li>- Boston Scientific : Cardiac Electrophysiology and Interventional Cardiology (Coronaries) (2015-2016)</li> </ul>
Demir Mesut	Nothing to be declared (2015-2016)
Dimmer Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biotronik : Pacemaker, ICD (2015)</li> <li>- Biotronik : Pacemaker (2016)</li> </ul>
Dobrev Dobromir	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- OMEICOS : Honoraria for consultancy services (2015)</li> <li>- Daiichi Sankyo : Honoraria for educational lectures (2015)</li> <li>- Welcome Trust : Honoraria for reviewer services (2015)</li> <li>- Else-Kröner Fresenius Stiftung : Honoraria for reviewer services (2015)</li> <li>- OMEICOS Therapeutics GmbH : antiarrhythmic drugs (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Xention : antiarrhythmic drugs (2016)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Ono Pharmaceuticals : antiarrhythmic drugs (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Duncan Edward	Nothing to be declared (2015) Declaration not submitted (2016)
Etsadashvili Kakhaber	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril, Ivabradine, (2015-2016)
Ferro Jose Manuel	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : NOACs (2015-2016)
Filippatos Gerasimos	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : Heart failure (2015-2016) - Servier : Heart failure (2015-2016) - Cardioentis : Heart failure (2015-2016) - Corthera, Novartis : Heart failure (2015-2016) E - Research funding (personal). - European Union : Heart failure (2015-2016)
Fitzsimons Donna	Nothing to be declared (2016) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : lipid management (2015)
Gorenek Bulent	Nothing to be declared (2015) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : ANTITHROMBOTIC THERAPY (2016) - Bayer : ATRIAL FIBRILLATION (2016) - Pfizer : ATRIAL FIBRILLATION (2016)
Grosu Aurel	Nothing to be declared (2015-2016)
Guenoun Maxime	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : cardiology (2015) - Astra Zeneca : cardiology (2015-2016) - Boehringer-Ingelheim : cardiology (2015-2016)

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Guenoun Maxime	<ul style="list-style-type: none"> <li>- Pfizer : cardiology (2015-2016)</li> <li>- Meda pharma : cardiology (2015-2016)</li> <li>- Bayer Healthcare : cardiology (2015-2016)</li> <li>- Bristol Myers Squibb : cardiology (2015-2016)</li> <li>- Medtronic : pacing (2015-2016)</li> <li>- Sorin Group : pacing (2015-2016)</li> </ul>
Hayrapetyan Hamlet	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Arterial Hypertension (2015)</li> <li>- Servier : Arterial Hypertension, Ischemic heart disease (2016)</li> <li>- Takeda Pharmaceuticals : Ischemic heart disease (2016)</li> <li>- Bayer : NOAC (2016)</li> </ul>
Hedman Antti	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiome UK : Antiarrhythmics (2015)</li> <li>- Boehringer-Ingelheim : Anticoagulants (2015)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulants (2015)</li> <li>- St Jude Medical : Rhythm managemet devices, LAA occluders (2015-2016)</li> </ul>
Hemels Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Advisory Board fee (2015)</li> <li>- Daiichi Sankyo : Advisory Board fee, speakers fee/consultancy (2015)</li> <li>- Sorin Group : Speakers fee/consultancy (2015)</li> <li>- Biotronik : Speakers fee/consultancy (2015)</li> <li>- Pfizer : Advisory Board fee, speakers fee/consultancy (2015-2016)</li> <li>- Bayer Netherlands : Speakers fee/consultancy (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hemels Martin	<ul style="list-style-type: none"> <li>- Daiichi Sankyo : Advisory Board fee (2016)</li> <li>- Boehringer-Ingelheim : Speakers fee/consultancy (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Participation GLORIA AF study (2015-2016)</li> </ul>
Hlivak Peter	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : speaker fees: SPAF - thromboprophylaxis in AF (2015-2016)</li> <li>- Pfizer : speaker fees: SPAF - thromboprophylaxis in AF (2015-2016)</li> </ul>
Hohnloser Stefan H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : antiarrhythmics (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant (2015)</li> <li>- Daiichi Sankyo : anticoagulant (2015)</li> <li>- Janssen-Cilag : anticoagulant (2015)</li> <li>- Bristol Myers Squibb : anticoagulant (2015)</li> <li>- St Jude Medical : ICD (2015)</li> <li>- Medtronic : ICD, loop recorder (2015)</li> <li>- Bayer Healthcare : anticoagulant (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : anticoagulant (2016)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : anticoagulant (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : anticoagulant (2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : antiarrhythmics (2016)</li> <li>- Janssen-Cilag : anticoagulant (2016)</li> <li>- Medtronic : CRM devices (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Hohnloser Stefan H	- St Jude Medical : CRM devices (2016)
Kalejs Oskars	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Cardiovascular Pharmacotherapy (2015-2016)</li> <li>- Pfizer : Cardiovascular Pharmacotherapy (2015-2016)</li> <li>- Abbott : Cardiovascular Pharmacotherapy. (2015-2016)</li> <li>- Boehringer-Ingelheim : Cardiovascular Pharmacotherapy. (2015-2016)</li> <li>- Novartis : Cardiovascular Pharmacotherapy. (2015-2016)</li> <li>- Servier : Cardiovascular Pharmacotherapy. (2015-2016)</li> <li>- Bayer AG : Cardiovascular Pharmacotherapy. (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosense Webster : Treatment of Atrial Fibrillation, Catheter Ablation (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Latvian Research Institute of Cardiology : Treatment of Heart Failure (2015-2016)</li> </ul>
Kampus Priit	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Berlin Chemie AG : Central blood pressure and betablockers (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Estonian Research Council : Arterial stiffness and blood pressure (2015-2016)</li> <li>- Berlin Chemie AG : Central blood pressure and betablockers (2015-2016)</li> </ul>
Keane David Tj	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- lake regional medical : arrhythmias - consultancy (2015-2016)</li> <li>- Johnson &amp; Johnson : arrhythmias - speaker (2015-2016)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Medtronic : Ablation - investigational (2015-2016)</li> </ul>
Khaled Said	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zenica : Pharmacy (2015)</li> <li>- Astra Zenica, Novartis, Sanofi, Pfizer : Pharmacy (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2015-2016)</li> <li>- B.Braun : Surgical instruments (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : Cardiac valves (2015)</li> <li>- Edwards Lifesciences : Cardiac valves (2015-2016)</li> </ul>
Koshumbayeva Kulzida	<p>Nothing to be declared (2015)</p> <p>Declaration not submitted (2016)</p>
Le Heuzey Jean-Yves	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : antiarrhythmics (2015-2016)</li> <li>- Sanofi Aventis : antiarrhythmics (2015-2016)</li> <li>- Meda pharma : antiarrhythmics (2015-2016)</li> <li>- Correvio : antiarrhythmics (2015-2016)</li> <li>- Astra Zeneca : antithrombotics (2015-2016)</li> <li>- Bayer : antithrombotics (2015-2016)</li> <li>- Daiichi Sankyo : antithrombotics (2015-2016)</li> <li>- BMS/Pfizer : antithrombotics (2015-2016)</li> <li>- Boehringer Ingelheim : antithrombotics (2015-2016)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2015)</li> <li>- Biotronik : atrial fibrillation (2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2015)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	<ul style="list-style-type: none"> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2015)</li> <li>- Medtronic : AF screening (2016)</li> <li>- BMS/Pfizer : Anticoagulation (2016)</li> <li>- Daiichi-Sankyo : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Bayer/Janssen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2015)</li> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> <li>- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)</li> </ul>
Loncar Daniela	Nothing to be declared (2015-2016)
Mairesse Georges H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : cardiovascular drugs (2015)</li> <li>- Johnson &amp; Johnson : AF (2015-2016)</li> <li>- Boehringer-Ingelheim : NOAC (2015-2016)</li> <li>- Daiichi Sankyo : NOAC (2015-2016)</li> <li>- Bayer Healthcare : NOAC (2015-2016)</li> <li>- Bristol Myers Squibb : NOAC (2015-2016)</li> <li>- Medtronic : pacemakers (2015-2016)</li> <li>- Sorin Group : pacemakers (2015-2016)</li> <li>- Biotronik : pacemakers - telemonitoring (2015-2016)</li> <li>- St Jude Medical : pacemakers (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Mairesse Georges H	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Pacemaker and devices (2015)</li> <li>- Boehringer-Ingelheim : NOAC (2015-2016)</li> <li>- Bristol Myers Squibb : NOAC (2015-2016)</li> <li>- Sorin Group : Pacemaker (2015-2016)</li> <li>- St Jude Medical : Pacemaker (2015-2016)</li> <li>- Biotronik : pacemaker study (2015-2016)</li> <li>- Medtronic : pacemakers (2016)</li> </ul>
Manolis Athanasios John	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Hypertension, (2015)</li> <li>- Bayer AG : atrial fibrillation (2015-2016)</li> <li>- Servier : hypertension (2015-2016)</li> <li>- Berlin Chemie AG : hypertension (2015-2016)</li> <li>- Ferrer Internacional : hypertension (2015-2016)</li> <li>- Recordati International : hypertension (2015-2016)</li> <li>- Menarini : hypertension, heart failure (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bayer : AF (2015-2016)</li> <li>- Boehringer-Ingelheim : AF (2015-2016)</li> <li>- GlaxoSmithKline : Coronary Heart Disease (2015-2016)</li> <li>- Servier : Heart Failure (2015-2016)</li> <li>- Amgen : hyperlipidemia (2015-2016)</li> <li>- Sanofi Aventis : hyperlipidemia (2015-2016)</li> </ul>
Marinskis Germanas	Nothing to be declared (2016)



## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Marinskis Germanas	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - BackBeat Medical : Pacemaker (2015)</p>
McMurray John	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - GSK : albiglutide/prolyl hydroxylase inhibitor (Trial endpoint committee/executive committees) (2015-2016) - Novartis : aliskiren (Trial executive committee) (2015-2016) - Theracos : Bexagliflozin (Trial executive committee) (2015-2016) - Amgen Inc : omecamtiv mecarbil (Trial steering committee) (2015-2016) - Novartis : sacubitril/valsartan (Trial executive committee, advisory boards, lectures) (2015-2016) - Cardioentis : ularitide (Trial executive committee/to run endpoint committe) (2015-2016) - Oxford University/Bayer : Acarbose (ACE trial Steering Committee) (2016) - Abbvie (SONAR trial Steering Committee) : Atrasentan (2016) - Pfizer (SPIRE trial DSMB) : Bococizumab (2016) - DalCor (DalGenE Steering Committee) : Dalcetrapib (2016)</p>
Mikhaylov Evgeny	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : Medical devices (2015-2016) - Biosense Webster : Medical devices (2015-2016) - Boehringer-Ingelheim : Anticoagulation (2016) - Pfizer : Anticoagulation (2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2015-2016) - Biosense Webster : Medical devices (2015-2016)</p>
Mirrakhimov Aibek	Nothing to be declared (2015-2016)
Nasr Samer	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Devices(pacemakers, defibrillators) (2015) - Novartis : Entresto (2016)</p>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Nasr Samer	<ul style="list-style-type: none"> <li>- Bayer : Xarelto (2016)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</li> <li>- Astra Zeneca : Pharmaceutical donated 3000 us dollars to my institution(Mount Lebanon Hospital) for research (2015)</li> </ul>
Ouali Sana	<p>Nothing to be declared (2015)</p> <p>Declaration not submitted (2016)</p>
Pehrson Steen Michael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Speaker fee (2015)</li> <li>- Bayer Healthcare : Speaker fee (2015)</li> <li>- Bristol Myers Squibb : Speaker fee (2015)</li> <li>- Lundbeck : Speaker fee (2015)</li> <li>- Novo-Nordisk : Evaluation of scientific study (2016)</li> <li>- Servier : Speaker's fee (2016)</li> <li>- Bayer Healthcare : Speaker's fee (2016)</li> <li>- Bristol Myers Squibb : Speaker's fee (2016)</li> <li>- Lundbeck : Speaker's fee (2016)</li> </ul>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : devices (2015)</li> <li>- BioControl : devices (2015)</li> <li>- DC Device : devices (2015)</li> <li>- Bayer Healthcare : heart failure (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- CIBIEM : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- Respicardia : devices (2015-2016)</li> <li>- Novartis : heart failure (2015-2016)</li> <li>- Cardiorentis : heart failure (2015-2016)</li> <li>- Vifor Pharma ltd : heart failure (2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2015-2016)</li> <li>- Amgen : heart failure, lipids (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Celladon : heart failure (2015)</li> <li>- Amgen : heart failure, lipids (2015)</li> <li>- Respicardia : anticoagulant (2015-2016)</li> <li>- BioControl : devices (2015-2016)</li> <li>- DC Device : devices (2015-2016)</li> <li>- Novartis : heart failure (2015-2016)</li> <li>- Cardiorentis : heart failure (2015-2016)</li> <li>- Bayer Healthcare : heart failure (2015-2016)</li> <li>- CIBIEM : heart failure (2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2015-2016)</li> </ul>
Puposka Lidija	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAK (2015)</li> <li>- Bayer Schering Pharma : NOAK (2015)</li> <li>- Boehringer-Ingelheim : NOAC (2016)</li> <li>- Bayer Schering Pharma : NOAC (2016)</li> </ul>
Potpara Tatjana	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : stroke prevention in atrial fibrillation (2015)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Potpara Tatjana	<ul style="list-style-type: none"> <li>- Bayer : stroke prevention in atrial fibrillation (2015-2016)</li> <li>- Pfizer : stroke prevention in atrial fibrillation (2015-2016)</li> <li>- Astra Zeneca : stroke prevention in atrial fibrillation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Pfizer : atrial fibrillation (2016)</li> </ul>
Roithinger Franz Xaver	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Anticoagulation (2015-2016)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2015-2016)</li> <li>- Daiichi Sankyo : Anticoagulation (2015-2016)</li> <li>- Astra Zeneca : Platelet inhibition (2015-2016)</li> <li>- St. Jude Medical : Devices (2016)</li> <li>- Merck Ges m b H : Diabetes (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Anticoagulation (2015-2016)</li> <li>- Biotronik : Device Therapy (2015-2016)</li> <li>- Biosense Webster : Electrophysiology (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Electrophysiology (2015-2016)</li> <li>- Astra Zeneca : Platelet inhibition (2015-2016)</li> </ul>
Romeo Francesco	Nothing to be declared (2015-2016)
Rosenhek Raphael	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott : Valvular heart disease (2015)</li> <li>- Edwards Lifesciences : Valvular heart disease (2015-2016)</li> <li>- Sorin Group : Valvular heart disease (2015-2016)</li> <li>- Valtech : Valvular heart disease (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ruschitzka Frank	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Drugs (2015-2016)</li> <li>- Sanofi Aventis : Drugs (2015-2016)</li> <li>- Zoll Medical : LifeVest (2015-2016)</li> <li>- Heartware : Ventricular assist devices (2015-2016)</li> <li>- Amgen : Drug (2016)</li> <li>- Novartis : Drug (2016)</li> <li>- St. Jude Medical : Medical devices (2016)</li> <li>- Cardiorentis : TRUE-AHF (2016)</li> <li>- Cardiorentis : TRUE-AHF Steering Committee (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> <li>- Novartis : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> <li>- St Jude Medical : Postgraduate Heart Failure Course (Grant to Zurich Heart House) (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Mars : Flavanol-like cocoa products (2015-2016)</li> </ul>
Sammut Mark Adrian	<p>Nothing to be declared (2015)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Devices (2016)</li> </ul>
Savelieva Irene	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Anticoagulation (2015-2016)</li> <li>- Bayer Healthcare : Anticoagulation (2015-2016)</li> <li>- Biosense Webster : Ablation (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : Anticoagulation (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Shah Dipen	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Apixaban (2015-2016)</li> <li>- Medtronic : Cardiac EP (2015-2016)</li> <li>- Biosense Webster : Cardiac EP (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Cardiac EP (2015-2016)</li> <li>- St Jude Medical : Cardiac EP (2015-2016)</li> <li>- Biosense Webster : Cardiac EP (2015-2016)</li> </ul>
Shalghanov Tchavdar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actavis : Educational courses on ECG diagnostics of arrhythmias for general practitioners and cardiology residents (2015)</li> <li>- Bayer : rivaroxaban (2015-2016)</li> </ul>
Sharma Sanjay	Nothing to be declared (2015-2016)
Skoric Bosko	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Teva Pharmaceutical Industries Pliva : eplerenone (2015-2016)</li> <li>- Novartis : Exforge HCT (2016)</li> <li>- Berlin Chemie AG : zofenopril (2016)</li> </ul>
Sredniawa Beata	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pradaxa (2015-2016)</li> <li>- Bayer : Xarelto (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Therapeutic Hypothermia (2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Zoll Medical : Therapeutic Hypothermia (2015-2016)</li> </ul>
Suwalski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : cardiovascular surgery (2015-2016)</li> <li>- St Jude Medical : cardiovascular surgery (2015-2016)</li> <li>- Atricure : cardiovascular surgery (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sychoy Oleg	Nothing to be declared (2015-2016)
Taborsky Milos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : NOAC (2015-2016)</li> <li>- Pfizer : NOAC (2015-2016)</li> <li>- Bayer AG : NOAC (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : NOAC (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : AA drug (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biotronik : ICD an pacemakers (2015-2016)</li> </ul>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Menarini : Angina, diabetes (2015-2016)</li> <li>- Servier : Antiarrhythmic, angina (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Committee Member (2015)</li> </ul>
Taylor Clare	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Primary Care Cardiovascular Society : I coauthored the EPCCS guideline on stroke prevention in AF. EPCCS received an unrestricted educational grant from Bayer, Boehringer Ingelheim and Pfizer/BMS to support the costs. EPCCS approached the sponsors and the sponsors had no role in producing or commenting on the guidance. (2015-2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- National Institute for Health Research : I was funded by NIHR through a doctoral research fellowship. The department also received funding through this fellowship. (2015-2016)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- National Institute for Health Research : I was funded by NIHR through a doctoral research fellowship. (2015-2016)</li> </ul>
Van Gelder Isabelle C	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation (2015)</li> <li>- Bayer : atrial fibrillation (2015-2016)</li> <li>- BMS : atrial fibrillation (2015-2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Van Gelder Isabelle C	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2015-2016)</li> <li>- Dutch Heart Foundation : atrial fibrillation (2016)</li> </ul>
Voors Adriaan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Singulex : biomarkers (2015)</li> <li>- Novartis : Serelaxin/Aliskiren (Heart Failure) (2015)</li> <li>- Stealth : Bendavia drug development in heart failure (2015-2016)</li> <li>- Cardio3 Biosciences : C3S-CQS (Heart Failure) (2015-2016)</li> <li>- Vifor International : Ferric Carboxymaltose (Heart Failure) (2015-2016)</li> <li>- Bayer Healthcare : Finerenone (Heart Failure) (2015-2016)</li> <li>- Servier : Ivabradine (Heart Failure) (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : no product; speaker fees; Heart Failure (2015-2016)</li> <li>- Amgen : Omecamtic (Heart Failure) (2015-2016)</li> <li>- Trevena : TRV027 (Heart Failure) (2015-2016)</li> <li>- Novartis : Serelaxin/Aliskiren (Heart Failure) (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Partial adenosine A1-agonist (2015-2016)</li> <li>- Vifor Pharma : Speaker fees: Heart Failure (2015-2016)</li> <li>- Bristol Myers Squibb : CXL-1072, Heart Failure (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Singulex : Biomarkers in Heart Failure (2015-2016)</li> <li>- Sphingotec : Biomarkers in Heart Failure (2015-2016)</li> <li>- Servier : EDIFY study with Ivabradine in Heart Failure (2015-2016)</li> <li>- Vifor International : Heart Failure (2015-2016)</li> </ul>



## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Voors Adriaan	<ul style="list-style-type: none"> <li>- Bayer AG : Heart Failure (2015-2016)</li> <li>- Novartis : Heart Failure grant and RELAX-AHF (2015-2016)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet therapy (2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Biotronik : Electrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD : CV risk factors (2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> </ul>

## Guidelines on AFib 2016 (TF26) - Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- MSD : speaker. CV risk factors (2016)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2015)</li> <li>- Novartis : Clinical trial (2015)</li> <li>- Ikaria : Clinical trial (2015)</li> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul> </li> </ul>
Zavatta Marco	Nothing to be declared (2015-2016)
Zeppenfeld Katja	<ul style="list-style-type: none"> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Boston Scientific : ICD, pacemaker (2015-2016)</li> <li>- Medtronic : ICD, pacemaker (2015-2016)</li> <li>- Biotronic : ICD, pacemaker (2015-2016)</li> <li>- Edwards Lifesciences : percutaneous valve (2015-2016)</li> </ul> </li> </ul>
Zupan Igor	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Medtronic : CRT (2015)</li> <li>- Medtronic : CRT, ICD (2016)</li> <li>- Sorin Group : CRT, ICD (2016)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antithrombotics (2014)</li> <li>- Novartis : Hypertension (2014-2015)</li> <li>- Boehringer-Ingelheim : Oral anticoagulation (2014-2015)</li> <li>- Sanofi Aventis : Hyperlipidemia (2014-2015-2016)</li> <li>- Bayer Healthcare : Oral anticoagulation (2014-2015-2016)</li> <li>- Pfizer/BMS alliance : Oral anticoagulation (2014-2015-2016)</li> <li>- MSD : Antiplatelet therapy (2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- AbbiVie : cachexia (2016)</li> <li>- Novartis : Heart Failure (2016)</li> </ul>
Achenbach Stephan	<p>Nothing to be declared (2015-2016)</p> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2014)</li> </ul>
Agewall Stefan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Thermo Fischer Scientific : Cardiac markers (2014-2015)</li> <li>- Astra Zeneca : Platelet inhibition (2014-2015)</li> <li>- Vifor International : Heart failure (2015)</li> <li>- Astra Zeneca : Antiplatelet treatment (2016)</li> </ul>
Badimon Lina	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- MSD-España : Lipids (2014)</li> <li>- Sanofi Aventis : lipids (2014-2015-2016)</li> <li>- Burson Masteller : nutrition (2014-2015-2016)</li> <li>- Astra Zeneca : thrombosis (2014-2015-2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Badimon Lina	D - Research funding (departmental or institutional). - Astrazeneca : thrombosis (2014-2015-2016)
Baron Esquivias Gonzalo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2014-2015-2016) - Daiichi Sankyo : Anticoagulation (2014-2015-2016) - Pfizer : Anticoagulation (2014-2015-2016) - Bayer : Anticoagulation (2014-2016) - Merck Sharp & Dohme : Dyslipemia (2015-2016)
Baumgartner Helmut	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Direct Flow Medical : transcatheter valve implantation (2014-2015) - Actelion : Bosentan for PAH treatment in congenital heart disease (2014-2015-2016) - St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2014-2015-2016) - Abbott : transcather mitral valve repair (Mitraclip) (2014-2015-2016) - Edwards Lifesciences : transcatheter valve implantation (2014-2015-2016) - Gore : Occluders for shunt closure (2015-2016)
Bax Jeroen	Nothing to be declared (2014-2015-2016)
Bueno Hector	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer Healthcare : Aspirin, rivaroxaban (2014)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	<ul style="list-style-type: none"> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> <li>- Sanofi Aventis : Clopidogrel (2014-2015)</li> <li>- Daiichi Sankyo : Prasugrel (2014-2015)</li> <li>- Eli Lilly : Prasugrel (2014-2015)</li> <li>- Pfizer : Apixaban (2014-2015-2016)</li> <li>- Bristol Myers Squibb : Apixaban (2014-2015-2016)</li> <li>- Servier : ivabradine (2014-2015-2016)</li> <li>- Astra Zeneca : Ticagrelor (2014-2015-2016)</li> <li>- Bayer Healthcare : Aspirin (2015)</li> <li>- Novartis : Serelaxin, LCZ696 (2015)</li> <li>- Ferrer Internacional : Trinomia (polypill) (2015-2016)</li> <li>- Janssen-Cilag : GEMINI Trial - RIVAROXACS2002 (2016)</li> <li>- Novartis : Serelaxin, LCZ696, ACZ885, AHF Academy (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Ticagrelor (2015-2016)</p> <p>E - Research funding (personal). - Astra Zeneca : Ticagrelor (2014-2015-2016)</p>
Carerj Scipione	Nothing to be declared (2014-2015-2016)
Erol Cetin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2014-2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Menarini : Hypertension (2014-2015-2016)</p>
Fitzsimons Donna	Nothing to be declared (2016)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Fitzsimons Donna	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : FH Treatment options (2014) - Amgen : lipid management (2015)
Gaemperli Oliver	Nothing to be declared (2016)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biosensors : Stents (2014) - Abbott Vascular : MitraClip (2015) - Biosensors : Travel Grant to AsiaPCR 2015 (2015)
Kirchhof Paulus	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : cardiovascular (2014) - Pfizer : cardiovascular (2014) - Bristol Myers Squibb : cardiovascular (2014) - Medtronic : cardiovascular (2014-2015) - St Jude Medical : cardiovascular (2014-2015) - Sanofi Aventis : cardiovascular (2014-2015) - Meda pharma : cardiovascular (2014-2015) - Merck Sharp & Dohme : cardiovascular (2014-2015) - Medscape : cardiovascular (2014-2015) - Boehringer-Ingelheim : cardiovascular (2014-2015-2016) - Astra Zeneca : cardiovascular (2015) - Servier : cardiovascular (2015) - Bayer Vital : cardiovascular (2015) - Correvio : cardiovascular (2015) - Bristol Myers Squibb Global : cardiovascular (2015)

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Pfizer Germany : cardiovascular (2015)</li> <li>- Bayer Healthcare : cardiovascular (2015-2016)</li> <li>- Daiichi Sankyo Europe : cardiovascular (2015-2016)</li> <li>- Pfizer Global : cardiovascular (2015-2016)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Meda pharma : cardiovascular (2014-2015)</li> <li>- Daiichi Sankyo : cardiovascular (2014-2015-2016)</li> <li>- St Jude Medical : cardiovascular (2014-2015-2016)</li> <li>- Sanofi Aventis : cardiovascular (2014-2015-2016)</li> <li>- British Heart Foundation : cardiovascular (2014-2015-2016)</li> <li>- BMS / Pfizer alliance : cardiovascular (2014-2015-2016)</li> <li>- Leducq Foundation : cardiovascular (2014-2015-2016)</li> <li>- European Union FP7 : cardiovascular (2014-2015-2016)</li> <li>- European Union horizon2020 : cardiovascular (2014-2015-2016)</li> <li>- German Centre for Heart Research (DZHK, funded by German Ministry of Education and Research) : cardiovascular (2014-2015-2016)</li> <li>- UK Medical Research Council : cardiovascular (2015-2016)</li> </ul> </li> </ul>
Kolh Philippe H	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet agents (2014-2015-2016)</li> <li>- B.Braun : Surgical instruments (2014-2015-2016)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medtronic : Cardiac valves (2014-2015)</li> <li>- Edwards Lifesciences : Cardiac valves (2014-2015-2016)</li> </ul> </li> </ul>
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> </ul> </li> </ul>



## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>- Servier : Imaging Ischemic disease (2015)</li> <li>- Boston Scientific : Sudden death (2015)</li> <li>- St Jude Medical : Echo course (2015-2016)</li> <li>- Servier : Ischemic Heart Disease (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> <li>- Bayer : NOAC (2015-2016)</li> </ul>
Lip Gregory Y H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : atrial fibrillation (2014-2015)</li> <li>- Biotronik : atrial fibrillation (2014-2015)</li> <li>- Boehringer-Ingelheim : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Pfizer : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bayer Healthcare : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Bristol Myers Squibb : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Medtronic : AF screening (2016)</li> <li>- BMS/Pfizer : Anticoagulation (2016)</li> <li>- Daiichi-Sankyo : Anticoagulation (2016)</li> <li>- Boehringer Ingelheim : Anticoagulation (2016)</li> <li>- Bayer/Janssen : Anticoagulation (2016)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Daiichi Sankyo : atrial fibrillation, thrombosis (2014-2015)</li> <li>- Boehringer Ingelheim : AF Registries [unrestricted educational grant] (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lip Gregory Y H	- Daiichi-Sankyo : Systematic reviews [unrestricted educational grant] (2016)
Nihoyannopoulos Petros	Nothing to be declared (2014-2015-2016)
Piepoli Massimo Francesco	<p>Nothing to be declared (2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Servier : Cardiovascular Prevention and Rehabilitation Initiatives (2015-2016)            - Novartis : Heart Failure Prevention Initiatives (2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.            - Novartis : Heart Failure Prevention Initiatives (2015-2016)</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Boehringer-Ingelheim : anticoagulant (2014)</li> <li>- Respicardia : anticoagulant (2014)</li> <li>- Johnson &amp; Johnson : heart failure (2014)</li> <li>- Pfizer : heart failure, anticoagulant (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Abbott Vascular : devices (2014-2015)</li> <li>- Bayer Healthcare : heart failure (2014-2015)</li> <li>- CIBIEM : heart failure (2014-2015)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardioentis : heart failure (2014-2015-2016)</li> <li>- Vifor Pharma Ltd : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Amgen : heart failure, lipids (2014-2015-2016)</li> <li>- BioControl : devices (2015)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ponikowski Piotr	<ul style="list-style-type: none"> <li>- DC Device : devices (2015)</li> <li>- Celladon : heart failure (2015)</li> <li>- Pfizer : lipids (2015)</li> <li>- Boehringer-Ingelheim : anticoagulant, diabetes (2015-2016)</li> <li>- Respicardia : devices (2015-2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : acute coronary syndrome (2014)</li> <li>- Vifor Pharma ltd : heart failure (2014)</li> <li>- MSD : lipids (2014)</li> <li>- Amgen : heart failure, lipids (2014-2015)</li> <li>- Respicardia : anticoagulant (2014-2015-2016)</li> <li>- Novartis : heart failure (2014-2015-2016)</li> <li>- Cardioentis : heart failure (2014-2015-2016)</li> <li>- Bayer Healthcare : heart failure (2014-2015-2016)</li> <li>- CIBIEM : heart failure (2014-2015-2016)</li> <li>- Servier : heart failure, coronary artery disease (2014-2015-2016)</li> <li>- Celladon : heart failure (2015)</li> <li>- BioControl : devices (2015-2016)</li> <li>- DC Device : devices (2015-2016)</li> </ul>
Roffi Marco	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : coronary catheters (2014-2015-2016)</li> <li>- Astra Zeneca : speaker fees related to the 2015 ESC NSTEMI GL (2015-2016)</li> <li>- Terumo Inc : coronary catheters (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Roffi Marco	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Biosensors : devices (2014-2015-2016)</li> <li>- Boston Scientific : devices (2014-2015-2016)</li> <li>- Medtronic : devices (2014-2015-2016)</li> <li>- Biotronik : devices (2014-2015-2016)</li> <li>- Abbott Vascular : devices (2014-2015-2016)</li> <li>- Terumo Inc : devices (2015-2016)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2014)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2014)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2014-2015-2016)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2014-2015-2016)</li> <li>- Teva Pharmaceutical Industries : anti-cancer treatment (2015-2016)</li> <li>- Sanofi Aventis : anticoagulants (2015-2016)</li> <li>- AOP Orphan Pharmaceuticals : pulmonary arterial hypertension (2015-2016)</li> <li>- United Therapeutics : pulmonary hypertension (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer Healthcare : Pulmonary hypertension (2014-2015-2016)</li> </ul>
Vaz Carneiro Antonio	<p>Nothing to be declared (2015-2016)</p> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- AbbVie : Oncology (2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Eli Lilly : Antiplatelet therapy (2014)</li> <li>- Bayer Healthcare : Antithrombotic drug (2014)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Abbott : Stent and Heartvalvetherapy (2014)</li> <li>- Biosensors : Stents (2014)</li> <li>- Boston Scientific : Stents (2014)</li> <li>- Astra Zeneca : Antiplatelet therapy (2014-2015)</li> <li>- Daiichi Sankyo : Antiplatelet therapy (2015)</li> <li>- Boston Scientific : Complex PCI (2015)</li> <li>- Sanofi Aventis : Managing Dyslipidemia (2015)</li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Medicines Company : Antithrombotic therapy (2014)</li> <li>- Johnson &amp; Johnson : Catheters (2014)</li> <li>- Edwards Lifesciences : Heartvalves (2014)</li> <li>- St Jude Medical : OCT (2014)</li> <li>- Abbott : Stent (2014)</li> <li>- Biotronik : Stent (2014)</li> <li>- Boston Scientific : Stent and Heartvalves (2014)</li> <li>- Medtronic : Stent and Heartvalves (2014)</li> <li>- Sorin Group : Electrophysiology (2015)</li> <li>- Biotronik : Electrophysiology (2015)</li> <li>- Johnson &amp; Johnson : Electrophysiology and PCI (2015)</li> <li>- Guerbet : Imaging (2015)</li> <li>- Medicines Company : IMP (2015)</li> <li>- St Jude Medical : PCI (2015)</li> <li>- Medtronic : Structural Heart Disease (2015)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Novartis : IMP (2015-2016)</li> <li>- Actelion : IMP (2015-2016)</li> <li>- Merck Sharp &amp; Dohme : IMP (2015-2016)</li> <li>- Abbott : PCI and Structural Heart Disease (2015-2016)</li> <li>- Boston Scientific : Structural Heart Disease (2015-2016)</li> <li>- Edwards Lifesciences : Structural Heart Disease (2015-2016)</li> <li>- Symetis SA : Structural Heart Disease (2015-2016)</li> <li>- Astrazeneca : Antiplatelet therapy (2016)</li> <li>- Biotronik : Elektrophysiology (2016)</li> <li>- Amgen : General Cardiology (2016)</li> <li>- Takeda Pharmaceuticals : General Cardiology (2016)</li> <li>- Bristol Myers Squibb : General Cardiology (2016)</li> <li>- Bayer AG : General Cardiology (2016)</li> <li>- Biotest : General Cardiology (2016)</li> <li>- Comed : General Cardiology (2016)</li> <li>- Baxalta : General Cardiology (2016)</li> <li>- Medicure : General Cardiology (2016)</li> <li>- Sanofi Aventis : Heart Failure, General Cardiology (2016)</li> <li>- Qvanteq : Invasive Cardiology, PCI (2016)</li> <li>- St. Jude Medical : PCI (2016)</li> <li>- Medtronic : Structural Heart Disease (2016)</li> <li>- NVT AG : Structural Heart Disease (2016)</li> </ul>

## Committee for Practice Guidelines 2014-2016 - MEMBERS

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Windecker Stephan	<ul style="list-style-type: none"> <li>- Quintiles : Structural Heart Disease &amp; PCI (2016)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> <li>- Astra Zeneca : Speaker fee for 1 talk in 2014 (2014)</li> <li>- MSD : CV risk factors (2014-2015)</li> <li>- Abbott : Lecturing (2015)</li> <li>- Pfizer : Lecturing (2015)</li> <li>- Sorin Group : Respicardia echo protocol (2015)</li> <li>- Philips : 3D Echocardiography. (2016)</li> <li>- Servier : Clinical case presentation during ESC Cong 2016 (2016)</li> <li>- Pfizer : speaker CV risk factors. (2016)</li> <li>- MSD : speaker. CV risk factors (2016)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : 3d echo software and free style echo (2014-2015)</li> <li>- Toshiba medical imaging : Fusion Imaging (2015)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Amgen : Clinical trial (2014-2015)</li> <li>- Novartis : Clinical trial (2014-2015)</li> <li>- Ikaria : Clinical trial (2014-2015)</li> <li>- Edwards Lifesciences : Echo for TAVi assessment &amp; Epidemiology of Ao stenosis (2016)</li> <li>- Abbott : Epidemiology study of Mitral regurgitation (2016)</li> </ul>